Skip to main content

Main menu

  • Home
  • Articles
    • Current
    • Published Ahead of Print
    • Archive
    • Supplemental Issues
    • Collections - French
    • Collections - English
  • Info for
    • Authors & Reviewers
    • Submit a Manuscript
    • Advertisers
    • Careers & Locums
    • Subscribers
    • Permissions
  • About CFP
    • About CFP
    • About the CFPC
    • Editorial Advisory Board
    • Terms of Use
    • Contact Us
  • Feedback
    • Feedback
    • Rapid Responses
    • Most Read
    • Most Cited
    • Email Alerts
  • Blogs
    • Latest Blogs
    • Blog Guidelines
    • Directives pour les blogues
  • Mainpro+ Credits
    • About Mainpro+
    • Member Login
    • Instructions
  • Other Publications
    • http://www.cfpc.ca/Canadianfamilyphysician/
    • https://www.cfpc.ca/Login/
    • Careers and Locums

User menu

  • My alerts

Search

  • Advanced search
The College of Family Physicians of Canada
  • Other Publications
    • http://www.cfpc.ca/Canadianfamilyphysician/
    • https://www.cfpc.ca/Login/
    • Careers and Locums
  • My alerts
The College of Family Physicians of Canada

Advanced Search

  • Home
  • Articles
    • Current
    • Published Ahead of Print
    • Archive
    • Supplemental Issues
    • Collections - French
    • Collections - English
  • Info for
    • Authors & Reviewers
    • Submit a Manuscript
    • Advertisers
    • Careers & Locums
    • Subscribers
    • Permissions
  • About CFP
    • About CFP
    • About the CFPC
    • Editorial Advisory Board
    • Terms of Use
    • Contact Us
  • Feedback
    • Feedback
    • Rapid Responses
    • Most Read
    • Most Cited
    • Email Alerts
  • Blogs
    • Latest Blogs
    • Blog Guidelines
    • Directives pour les blogues
  • Mainpro+ Credits
    • About Mainpro+
    • Member Login
    • Instructions
  • RSS feeds
  • Follow cfp Template on Twitter
  • LinkedIn
  • Instagram
OtherCurrent Practice

Answer to Dermacase

Irina Turchin and Benjamin Barankin
Canadian Family Physician March 2007; 53 (3) 433;
Irina Turchin
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Benjamin Barankin
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • eLetters
  • Info & Metrics
  • PDF
Loading

2. Cutaneous lupus erythematosus (subacute)

Subacute cutaneous lupus erythematosus (SCLE) is characterized by erythematous, photosensitive, non-scarring lesions and systemic signs and symptoms, such as musculoskeletal complaints (arthralgia and arthritis), serologic abnormalities (anemia and thrombocytopenia), pleurisy, pericarditis, renal disease, and neurologic disease.1 About half of SCLE patients have 4 or more of the American College of Rheumatology’s criteria for systemic lupus erythematosus2; however, SCLE patients’ systemic disease tends to be much milder.1,3 Subacute cutaneous lupus erythematosus is primarily a disease of white women; mean age of onset is between the third and fifth decades.1,4 The prevalence of SCLE is estimated at 1 to 5 cases per 100 000 population.3

The primary lesions among patients with SCLE are erythematous papules or plaques covered with fine scale. Lesions can expand and coalesce into large plaques that mimic psoriasis (papulosquamous subtype, Figure 1) or can expand and clear centrally, producing large annular polycyclic lesions (annular-polycyclic subtype). The papulosquamous form is the most common, and most SCLE patients exhibit only 1 morphologic subtype of the disease.

Characteristic SCLE distribution is in sun-exposed areas: neck, face, extensor arms, dorsal hands, lower limbs, and scalp.5 The disease is often aggravated by trauma and light. Resolving SCLE lesions characteristically do not produce scarring or dermal atrophy but they might result in telangiectases and pigmentary changes.1 Other types of cutaneous lupus erythematosus lesions can be found in SCLE patients and include malar eruptions (Figure 2), periungual telangiectases, and livedo reticularis (Figure 3).5

Diagnosis

Diagnosis of SCLE is based on history, physical examination, and laboratory investigations. Many medications have been implicated in onset and exacerbation of disease; hydrochlorothiazide and terbinafine are the most common.1 Every newly diagnosed SCLE patient should be screened for underlying systemic lupus erythematosus.

Patients should be asked about photosensitivity, rashes, mucosal ulcerations, fatigue, arthralgia and arthritis, alopecia, and symptoms of associated systemic disease. A complete physical examination guided by history is advised.3 Several laboratory investigations can be of value in diagnosis of SCLE. An antinuclear antibody test is commonly positive in patients with SCLE, but is not diagnostic of the disease. Most SCLE patients have anti-Ro(SSA) autoantibodies, which are recognized as a characteristic marker of the disease. There is a strong association between SCLE and anti-Ro(SSA) autoantibodies, especially in patients negative for anti–double-stranded DNA.4 In addition, a complete blood count and differential count, serum chemistry profile, erythrocyte sedimentation rate assessment, and urinalysis are recommended to screen for systemic disease. Skin biopsy confirms the diagnosis. Referral to a dermatologist or rheumatologist is highly recommended to confirm an SCLE diagnosis and rule out systemic disease.4

Treatment

The goals of SCLE treatment are to halt disease progression and improve patients’ appearance. Patients should be educated about continuous use of sun-screen with a sun protection factor of at least 30, wearing clothing that provides protection from the sun, and avoiding heat and sun. Cosmetics can be used to camouflage dyspigmentation and telangiectases. Depending on the location of the affected area and the age of the patient, mid- to high-potency topical steroids can be used for localized disease. If they do not work, physicians with experience can try using intralesional triamcinolone acetonide.3 Occasionally, topical calcineurin inhibitors, such as topical tacrolimus, are used on the head and neck, axillae, or groin. If topical corticosteroid preparations are ineffective or a large body-surface area is involved, 20 to 40 mg of prednisone daily for 3 to 4 weeks, in tapering doses, can be administered to control the disease.1

Antimalarial agents, such as 200 to 400 mg of hydroxychloroquine daily, are first-line agents for systemic therapy.3 Other systemic therapies include methotrexate, azathioprine, retinoids, and dapsone. These drugs have been shown to be effective in some cases and in anecdotal reports for those resistant to antimalarials.1

  • Copyright© the College of Family Physicians of Canada

References

  1. ↵
    1. Fabbri P,
    2. Cardinali C,
    3. Giomi B,
    4. Caproni M
    . Cutaneous lupus erythematosus: diagnosis and management. Am J Clin Dermatol 2003;4(7):449-65.
    OpenUrlCrossRefPubMed
  2. ↵
    1. Tan EM,
    2. Cohen AS,
    3. Fries JF,
    4. Masi AT,
    5. McShane DJ,
    6. Rothfield NF,
    7. et al
    . The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
    OpenUrlPubMed
  3. ↵
    1. Drake LA,
    2. Dinehart SM,
    3. Farmer ER,
    4. Goltz RW,
    5. Graham GF,
    6. Hordinsky MK,
    7. et al
    . Guidelines of care for cutaneous lupus erythematosus. J Am Acad Dermatol 1996;34(5 Pt 1):830-6.
    OpenUrlCrossRefPubMed
  4. ↵
    1. Chlebus E,
    2. Wolska H,
    3. Blaszczyk M,
    4. Jablonska S
    . Subacute cutaneous lupus erythematosus: diagnostic criteria and therapeutic implications. J Am Acad Dermatol 1998;38(3):405-12.
    OpenUrlCrossRefPubMed
  5. ↵
    1. Patel P,
    2. Werth V
    . Cutaneous lupus erythematosus: a review. Dermatol Clin 2002;20(3):373-85.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

Canadian Family Physician: 53 (3)
Canadian Family Physician
Vol. 53, Issue 3
1 Mar 2007
  • Table of Contents
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on The College of Family Physicians of Canada.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Answer to Dermacase
(Your Name) has sent you a message from The College of Family Physicians of Canada
(Your Name) thought you would like to see the The College of Family Physicians of Canada web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Answer to Dermacase
Irina Turchin, Benjamin Barankin
Canadian Family Physician Mar 2007, 53 (3) 433;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Respond to this article
Share
Answer to Dermacase
Irina Turchin, Benjamin Barankin
Canadian Family Physician Mar 2007, 53 (3) 433;
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • 2. Cutaneous lupus erythematosus (subacute)
    • Diagnosis
    • Treatment
    • References
  • eLetters
  • Info & Metrics
  • PDF

Related Articles

  • Question: Can you identify this condition?
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Current Practice

  • Scurvy
  • Intraprofessional relationships
  • Lyme disease
Show more Current Practice

Dermacase

  • Question: Can you identify this condition?
  • Answer: Can you identify this condition?
  • Question: Can you identify this condition?
Show more Dermacase

Similar Articles

Navigate

  • Home
  • Current Issue
  • Archive
  • Collections - English
  • Collections - Française

For Authors

  • Authors and Reviewers
  • Submit a Manuscript
  • Permissions
  • Terms of Use

General Information

  • About CFP
  • About the CFPC
  • Advertisers
  • Careers & Locums
  • Editorial Advisory Board
  • Subscribers

Journal Services

  • Email Alerts
  • Twitter
  • LinkedIn
  • Instagram
  • RSS Feeds

Copyright © 2025 by The College of Family Physicians of Canada

Powered by HighWire